Advertisement

Related Videos

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




May
19
Today In Oncology
Providing Culturally Sensitive Palliative Care to Children With Cancer
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside